The phase 3 CYCLONE 2 trial found that adding the CDK4/6 inhibitor abemaciclib to abiraterone did not significantly prolong radiographic progression‑free survival in men with metastatic castration‑resistant prostate cancer and increased toxicity, including treatment‑related interstitial lung disease.